8-K: Catheter Precision Anticipates Record LockeT Sales in Q2 2025 Amid European Expansion and Capital Raise

Catheter Precision, a US-based medical device company, projects its highest LockeT sales to date in Q2 2025, driven by strong hospital demand and European market expansion, while also filing a legal opinion related to an 'at-the-market' common stock offering.

Summary

• Catheter Precision, Inc. (VTAK) anticipates Q2 2025 LockeT sales to be the highest to date, already outpacing Q2 2024 sales by more than $84,000.
• Three U.S. hospitals, Montefiore (Bronx, NY), Eisenhower Health (Rancho Mirage, CA), and Overland Park Regional Medical Center (Overland Park, KS), are each on track to issue more than $100,000 in purchase orders for LockeT by the end of 2025.
• LockeT has received CE Mark approval, enabling sales in Europe, and the company has secured a new distributor in Italy, with additional distributors anticipated soon for Spain, Portugal, and the UK.
• The company is actively seeking distribution partners in other European Union countries to expand its footprint.
• A live case demonstration of LockeT with a key opinion leader is scheduled for Monday, June 16, during an Italian symposium to increase market awareness.
• Catheter Precision is registering the offer and sale of up to an additional $1,895,679 of common stock through a shelf Registration Statement on Form S-3 and an At Market Offering Agreement with Ladenburg Thalmann & Co. Inc.
• A legal opinion from Arnall Golden Gregory LLP confirms that the shares, when issued and delivered, will be validly issued, fully paid, and nonassessable.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to anticipated record sales for LockeT, significant year-over-year sales growth, strong commitments from key hospitals, successful European market entry with CE Mark and new distributors, and a capital raise providing financial flexibility for continued growth.

Positives

• Anticipated highest LockeT sales to date in Q2 2025, indicating strong product adoption and market traction.
• Q2 2025 sales already exceeding Q2 2024 sales by over $84,000, demonstrating significant year-over-year growth.
• Commitments from three U.S. hospitals for over $100,000 each in LockeT purchase orders by year-end 2025, signaling strong institutional demand.
• Successful receipt of CE Mark approval for LockeT, opening up the lucrative European market.
• Establishment of a new distributor in Italy and anticipated expansion into Spain, Portugal, and the UK, indicating successful international market entry.
• Scheduled live case demonstration at an Italian symposium with a key opinion leader, expected to boost product awareness in new markets.
• The 'at-the-market' offering provides capital flexibility to support ongoing growth and expansion initiatives.

Risks

• Forward-looking statements are subject to substantial risks and uncertainties, and actual outcomes may differ materially from expectations.
• The company's expectations and beliefs regarding product evaluations at hospitals and the value/benefits of LockeT may not materialize.
• Risks and uncertainties are detailed under the 'Risk Factors' caption in the company's Form 10-K filed with the SEC.

Future Outlook

Catheter Precision aims to continue improving product awareness, increasing product usage, and expanding its footprint into Europe. The company anticipates continued strong sales trajectory for LockeT, supported by new hospital adoptions and international distribution efforts.

Management Comments

• David Jenkins, CEO of Catheter Precision, stated: "We are excited about the upcoming activities, sales pipeline and expanded use by existing customer to increase revenue generated by LockeT."
• David Jenkins also noted: "At this time, there is a live case scheduled on Monday, June 16 with a key opinion leader where he will demonstrate LockeT during an Italian symposium, increasing its awareness to the new market."
• David Jenkins further commented: "As a company, we continue to focus on improving product awareness, increasing product usage and expanding our footprint into Europe."

Industry Context

This announcement positions Catheter Precision as an active innovator in the cardiac electrophysiology market, specifically addressing wound closure post-percutaneous venous punctures with its LockeT device. The expansion into Europe, following CE Mark approval, aligns with a broader trend of medical device companies seeking international growth opportunities to diversify revenue streams and tap into new healthcare markets. The focus on increasing product awareness and usage reflects a common strategy for medical device companies to drive adoption within the clinical community.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or detailed industry benchmarks to assess Catheter Precision's sales performance against global standards.
• However, the reported growth of LockeT sales, with Q2 2025 outpacing Q2 2024 by over $84,000 and commitments from three hospitals for over $100,000 each by year-end, suggests strong adoption within its niche, which is generally positive for a medical device company in its growth phase.

Stakeholder Impact

• Shareholders: Positive impact due to strong sales growth, market expansion, and a capital raise that can fund future initiatives, potentially leading to increased shareholder value.
• Customers (Hospitals/Clinicians): Positive impact as increased product availability and awareness of LockeT can improve patient care outcomes related to wound closure.
• Employees: Positive impact as company growth and expansion may lead to job security and potential opportunities.
• Creditors: Neutral to positive, as the capital raise strengthens the company's financial position.

Next Steps

• Secure additional distributors in Spain, Portugal, the UK, and other EU countries.
• Conduct a live case demonstration of LockeT with a key opinion leader during an Italian symposium on June 16.
• Continue to focus on improving product awareness and increasing product usage.
• Issue and deliver shares of common stock against payment in accordance with the Sales Agreement and Board resolutions.

Key Dates

Recommendation

Keywords

Catheter Precision, VTAK, LockeT, medical device, cardiac electrophysiology, suture retention device, SEC filing, 8-K, sales growth, market expansion, CE Mark, FDA, capital raise, common stock offering, hospital sales, distributor network